论文部分内容阅读
目的观察参附注射液与马来酸桂哌齐特联合治疗冠心病的疗效。方法选择符合诊断标准的病例共128例,随机分为对照组50例,治疗组78例。对照组采用常规治疗基础上加用马来酸桂哌齐特,治疗组在上述治疗的基础上加用参附注射液,疗程为2周。结果治疗组与对照组相比较,能显著改善患者的症状,总有效率分别为92.3%和66%,两组比较差异有统计学意义(P(0.05)。结论参附注射液与马来酸桂哌齐特联合治疗冠心病安全有效。
Objective To observe the curative effect of Shenfu injection combined with Cinepazide Maleate in the treatment of coronary heart disease. Methods A total of 128 cases with diagnostic criteria were selected and randomly divided into control group (n = 50) and treatment group (n = 78). The control group was treated with cinepazide maleate on the basis of conventional treatment. The treatment group was given Shenfu injection on the basis of the above treatment, and the course of treatment was 2 weeks. Results Compared with the control group, the treatment group could significantly improve the symptoms of the patients, the total effective rates were 92.3% and 66%, respectively, with significant difference between the two groups (P <0.05) .Conclusion Shenfu Injection and maleic acid Cinepazide combined treatment of coronary heart disease is safe and effective.